Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

861 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Inherited determinants of Crohn's disease and ulcerative colitis phenotypes: a genetic association study.
Cleynen I, Boucher G, Jostins L, Schumm LP, Zeissig S, Ahmad T, Andersen V, Andrews JM, Annese V, Brand S, Brant SR, Cho JH, Daly MJ, Dubinsky M, Duerr RH, Ferguson LR, Franke A, Gearry RB, Goyette P, Hakonarson H, Halfvarson J, Hov JR, Huang H, Kennedy NA, Kupcinskas L, Lawrance IC, Lee JC, Satsangi J, Schreiber S, Théâtre E, van der Meulen-de Jong AE, Weersma RK, Wilson DC; International Inflammatory Bowel Disease Genetics Consortium; Parkes M, Vermeire S, Rioux JD, Mansfield J, Silverberg MS, Radford-Smith G, McGovern DP, Barrett JC, Lees CW. Cleynen I, et al. Among authors: vermeire s. Lancet. 2016 Jan 9;387(10014):156-67. doi: 10.1016/S0140-6736(15)00465-1. Epub 2015 Oct 18. Lancet. 2016. PMID: 26490195 Free PMC article.
Serological diagnosis of inflammatory bowel disease.
Rutgeerts P, Vermeire S. Rutgeerts P, et al. Among authors: vermeire s. Lancet. 2000 Dec 23-30;356(9248):2117-8. doi: 10.1016/s0140-6736(00)03488-7. Lancet. 2000. PMID: 11191535 No abstract available.
Chromosome 3p and inflammatory bowel disease.
Satsangi J, Vermeire S. Satsangi J, et al. Among authors: vermeire s. Gut. 2001 Sep;49(3):455. doi: 10.1136/gut.49.3.455. Gut. 2001. PMID: 11550665 Free PMC article. No abstract available.
Serological markers for prediction of response to anti-tumor necrosis factor treatment in Crohn's disease.
Esters N, Vermeire S, Joossens S, Noman M, Louis E, Belaiche J, De Vos M, Van Gossum A, Pescatore P, Fiasse R, Pelckmans P, Reynaert H, Poulain D, Bossuyt X, Rutgeerts P; Belgian Group of Infliximab Expanded Access Program in Crohn's Disease. Esters N, et al. Among authors: vermeire s. Am J Gastroenterol. 2002 Jun;97(6):1458-62. doi: 10.1111/j.1572-0241.2002.05689.x. Am J Gastroenterol. 2002. PMID: 12094865 Free article.
NOD2/CARD15 does not influence response to infliximab in Crohn's disease.
Vermeire S, Louis E, Rutgeerts P, De Vos M, Van Gossum A, Belaiche J, Pescatore P, Fiasse R, Pelckmans P, Vlietinck R, Merlin F, Zouali H, Thomas G, Colombel JF, Hugot JP; Belgian Group of Infliximab Expanded Access Program and Fondation Jean Dausset CEPH, Paris, France. Vermeire S, et al. Gastroenterology. 2002 Jul;123(1):106-11. doi: 10.1053/gast.2002.34172. Gastroenterology. 2002. PMID: 12105838 Free article.
Demographic and clinical parameters influencing the short-term outcome of anti-tumor necrosis factor (infliximab) treatment in Crohn's disease.
Vermeire S, Louis E, Carbonez A, Van Assche G, Noman M, Belaiche J, De Vos M, Van Gossum A, Pescatore P, Fiasse R, Pelckmans P, Reynaert H, D'Haens G, Rutgeerts P; Belgian Group of Infliximab Expanded Access Program in Crohn's Disease. Vermeire S, et al. Am J Gastroenterol. 2002 Sep;97(9):2357-63. doi: 10.1111/j.1572-0241.2002.05991.x. Am J Gastroenterol. 2002. PMID: 12358256 Free article.
861 results